Legend Biotech reports strong preliminary CARVYKTI sales of $524m

Legend Biotech Corporation, an associate of Genscript Biotech Corporation, has reported preliminary net trade sales of approximately $524 million for its drug CARVYKTI® during the quarter ended September 30, 2025. This information was disclosed in a Form 6-K filing with the U.S. Securities and Trade Commission (SEC) on October 14, 2025.

The reported sales figure is derived from the Collaboration and License Agreement dated December 21, 2017, between Legend and Janssen Biotech, Inc. Genscript Biotech noted that neither Legend nor the company has independently verified the accuracy of this sales figure, which was provided by Janssen.

Genscript Biotech Corporation has advised shareholders and potential investors to be aware of investment risks and exercise caution when dealing in the company’s securities, particularly given that these statements are forward-looking and actual results may differ materially.